ABUS vs CHPT · P/E 5.4, rev $6.2M vs rev $417.1M
Arbutus Biopharma Corp (ABUS) versus ChargePoint Holdings Inc (CHPT) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
ChargePoint Holdings Inc (CHPT) is a specialty retail company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CHPT revenue for 2025-01-31 was $417.1M. Net income was -$277.1M. Revenue was down 17.7% from 2024-01-31 to 2025-01-31. CHPT currently screens at market cap $199.2M.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CHPT currently screens at market cap $199.2M.
Not investment advice. Open the ABUS and CHPT stock pages for the full models.
Not investment advice.